+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05615974

Phase III Study of LM-101 Injection Alone or with Other Drugs for Advanced Malignant Tumors Evaluating Safety, Dosage, Effects, and Immune Response

Led by LaNova Medicines Limited · Updated on 2024-12-19

139

Participants Needed

5

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying LM-101, a drug given intravenously, to evaluate its safety, tolerability, and appropriate dosing in adults with advanced malignant tumors that have not responded to standard treatments. This phase III open-label trial aims to find the maximum tolerated dose or recommended phase 2 dose of LM-101 alone or combined with other therapies. The study is sponsored by LaNova Medicines Limited and includes patients with confirmed recurrent or refractory solid tumors. Participants will receive LM-101 as a single agent or combined with drugs like Toripalimab or Rituximab, also administered intravenously. The study includes dose escalation, combination therapy exploration, and expansion phases. Treatment schedules and doses will be adjusted based on patient response and safety monitoring throughout the study period. During the trial, participants will undergo regular safety assessments including vital signs, laboratory tests, electrocardiograms, and heart function scans for up to 48 weeks. Researchers will also monitor tumor response and survival outcomes for up to 64 weeks, along with detailed pharmacokinetic and immunogenicity studies for up to 112 weeks. The total participation time varies by individual and includes ongoing evaluations of treatment effects and adverse events.

CONDITIONS

Brief Title

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Research Team

A

Alex Yuan

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here